KYTX

Kyverna TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$16.00

+102.5% vs current

Most likely

Base case

45%

Probability

Target price

$10.50

+32.9% vs current

B-

Bear case

30%

Probability

Target price

$5.50

-30.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Primary-source evidence supports real near-term upside optionality, but this still looks like a cautious monitoring setup rather than a high-conviction long. The March 26, 2026 filing package gives concrete catalyst dates and runway support, yet the deterministic score remains directionally negative with only moderate evidence quality and catalyst density, so the thesis should stay tempered until April data and the SPS filing are actually delivered.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-21catalystAAN presentations on KYSA-6 and KYSA-8 in April 2026High impact

Kyverna said updated Phase 2 KYSA-6 gMG data will be presented on April 20, 2026 and the primary analysis from the registrational KYSA-8 SPS trial will be presented on April 21, 2026 at AAN; those disclosures are the nearest hard catalysts for sentiment and can quickly reset expectations around efficacy, durability, and tolerability [#8-K-2026-03-26].

2026-06-30eventSPS BLA filing target in 1H 2026High impact

Management reiterated plans to submit its first BLA for SPS in the first half of 2026 after positive registrational KYSA-8 data; a successful filing would materially de-risk the lead program, while any slip or extra FDA asks would likely pressure the stock [#10-K-2026-03-26] [#8-K-2026-03-26].

2026-12-31catalyst2026 execution proof on gMG scale-up and broader autoimmune platformHigh impact

Kyverna has begun Phase 3 enrollment in gMG, had 14 active sites across three geographies as of the March 26, 2026 update, and says year-end 2025 cash should fund the SPS filing/commercial launch and the Phase 3 gMG trial into 2028; sustained enrollment progress plus additional 2026 platform readouts could support a rerating, but execution remains exposed to burn, dilution, and debt-covenant risk [#8-K-2026-03-26] [#10-K-2026-03-26].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology